论文部分内容阅读
目的:观察多西紫杉醇联合卡铂(DC方案)与长春瑞宾联合顺铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效、毒副反应。方法:67例晚期NSCLC患者分为两组,DC组33例,NP组34例,化疗2周期后评价疗效。结果:总有效率DC组39%,NP组35%,1年生存率DC组36%,NP组32%,两组比较差异均无显著性(P>0.05)。Ⅲ～Ⅳ度白细胞下降率DC组9%,NP组35%,两组差异有显著性(P<0.01);Ⅲ～Ⅳ度恶心、呕吐发生率DC组9%,NP组35%,两组差异有显著性(P<0.01)。结论:DC方案和NP方案治疗晚期NSCLC近期疗效肯定且相似,1年生存率也相似,但DC组严重的骨髓抑制及严重的胃肠反应发生率均低于NP组,患者更易耐受DC化疗方案。
Objective: To observe the efficacy and side effects of docetaxel combined with carboplatin (DC) and vinorelbine plus cisplatin (NP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Sixty-seven patients with advanced NSCLC were divided into two groups: 33 cases in DC group and 34 cases in NP group. After 2 cycles of chemotherapy, the curative effect was evaluated. Results: The total effective rate was 39% in DC group, 35% in NP group, 36% in 1-year survival group and 32% in NP group. There was no significant difference between the two groups (P> 0.05). The grade Ⅲ ~ Ⅳ leukopenia was 9% in the DC group and 35% in the NP group, with significant difference between the two groups (P <0.01). The incidence of grade Ⅲ ~ Ⅳ nausea and vomiting was 9% in the DC group and 35% in the NP group The difference was significant (P <0.01). CONCLUSION: The immediate and similar efficacy of DC regimen and NP regimen in the treatment of advanced NSCLC is similar and the one-year survival rates are similar. However, the severe myelosuppression and severe gastrointestinal reactions in DC group were lower than those in NP group, and the patients were more likely to tolerate DC chemotherapy Program.